Microtubule actin crosslinking factor 1 (MACF1), which was detected as a DEP only in the BrM/Glioma group, was found in previous studies to be a target for GBM.[47] Collectively, our study has provided compelling non‐invasive biomarkers, enabling precise differentiation between BrMs and gliomas. Here, MACF1 is linked to central nervous system cancer.